行情

EXEL

EXEL

伊克力西斯
NASDAQ

实时行情|Nasdaq Last Sale

15.34
-0.21
-1.35%
盘前: 15.34 0 0.00% 08:00 11/13 EST
开盘
15.60
昨收
15.55
最高
15.77
最低
15.26
成交量
226.98万
成交额
--
52周最高
25.31
52周最低
15.02
市值
46.61亿
市盈率(TTM)
7.84
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EXEL 新闻

  • Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019
  • Business Wire.16小时前
  • Exelixis' Cabometyx OK'd in Canada for second-line liver cancer
  • Seeking Alpha - Article.22小时前
  • Exelixis: Treatment Paradigm Winds See Cabomeytx Falling Flat, For Now
  • Seeking Alpha - Article.1天前
  • Exelixis Partner Ipsen Announces Health Canada Approval Of CABOMETYX Tablets For The Treatment Of Patients With Previously Treated Advanced Hepatocellular Carcinoma
  • Benzinga.1天前

更多

所属板块

生物技术和医学研究
+0.28%
制药与医学研究
+0.27%

热门股票

名称
价格
涨跌幅

EXEL 简况

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
展开

Webull提供Exelixis, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。